Its usefulness in breast cancer has been firmly established (Bidard et al, 2014), although its dependence on positive selection of EpCAM-positive CTCs may lead to false-negative or false-low CTC results in some patients (Sieuwerts et al, 2009). Here, EPCAM is linked to breast carcinoma.